Compare · BDX vs KMTS
BDX vs KMTS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 30.9x KMTS ($1.71B).
- BDX has been more active in the news (9 items in the past 4 weeks vs 6 for KMTS).
- BDX has more recent analyst coverage (25 ratings vs 9 for KMTS).
- Company
- Becton Dickinson and Company
- Kestra Medical Technologies Ltd.
- Price
- $191.68-1.09%
- $27.16-5.20%
- Market cap
- $52.78B
- $1.71B
- 1M return
- +5.72%
- -
- 1Y return
- +1.38%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest KMTS
- Director Cohen Raymond W sold $97,504 worth of shares (3,330 units at $29.28), decreasing direct ownership by 6% to 54,790 units (SEC Form 4) (tax liability)
- Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- Director Kwo Elizabeth sold $97,268 worth of shares (4,010 units at $24.26), decreasing direct ownership by 22% to 14,116 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- SEC Form 10-Q filed by Kestra Medical Technologies Ltd.
- Kestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
- Director Schwartz Jeffrey Lawrence sold $97,942 worth of shares (3,890 units at $25.18) and was granted 7,217 shares, increasing direct ownership by 30% to 14,236 units (SEC Form 4) to satisfy tax liability